Skip to main content
. Author manuscript; available in PMC: 2019 Sep 3.
Published in final edited form as: Clin Cancer Res. 2018 Sep 4;24(24):6265–6276. doi: 10.1158/1078-0432.CCR-18-0444

Figure 3. CIP2A is directly regulated by HOXB13 at transcriptional level.

Figure 3.

A. ChIP-seq assays indicate strong binding of HOXB13 at CIP2A gene in prostate cancer cells and tissue (data sets from refs. (48) and (6)).

B. ChIP-qPCR of HOXB13 at CIP2A in the PrCa LNCaP and 22Rv1 cell lines. ** p < 0.01; *** p < 0.001, ****p<0.0001

C-E. ChIP-qPCR at CIP2A in the PrCa LNCaP (C), and 22Rv1 cells (D) and immortalized benign prostate RWPE1 (E) cell line overexpressing V5 tagged HOXB13 or G84E. *p<0.05, ** p < 0.01; *** p < 0.001, from two-tailed t-tests. NS, not significant.

F-G. Real time qPCR analyses reveal markedly reduced mRNA levels of CIP2A (KIAA1524) upon knockdown of HOXB13 both in the LNCaP (siRNA) and 22Rv1 (shRNA) prostate cancer cell lines. Western blot results indicate depletion of HOXB13 in the PrCa LNCaP (siRNA) and 22Rv1 (shRNA) cell lines. Error bars, s.e.m. ** p < 0.01, *** p < 0.001, two-tailed student t-test.